NKTX
$2.32
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Recent News
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
On Jan. 21, 2026, the market weighed ImmunityBio’s skyrocketing share price, surging volume, and the company's heavily-shorted stock.
We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta Inc. (NASDAQ:NKTX) on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents. As of March 31, 2025, Nkarta had $351.9 million in cash, cash equivalents, restricted cash, and investments in marketable securities. The company expects its current cash and cash equivalents to be sufficient to fund its current operating plan into 2029. Also Read: Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? In the clinical development